Introduction
============

Cerebral corticogenesis requires precise spatio-temporal control of the rates of progenitor cell division. Previous research on the developing mouse embryo established that the transcription factor Pax6 is a key regulator of this process ([@B12]; [@B42]; [@B9]; [@B14]; [@B13]; [@B27], [@B28]; [@B36]; [@B38]; [@B2]; [@B10],[@B11]; [@B30]). Pax6 is expressed by cortical radial glial progenitors, which are by far the most numerous cortical cell type present at the onset of corticogenesis at around embryonic day 12.5 (E12.5) in mouse. Previous functional studies have shown that Pax6 is an important cell autonomous repressor of radial glial cell cycle progression ([@B42]; [@B9]; [@B27]; [@B11]; [@B30]). Loss of Pax6 shortens the overall length of cortical progenitor cell cycles and hence accelerates cell division ([@B30]). Previously, we identified a number of highly conserved cell cycle genes with actions fundamental to cell cycle progression across cell types and species whose levels of expression are affected by constitutive loss of Pax6 function ([@B32], [@B33]). One of these was the cell cycle gene Cdk6 ([@B30]).

Cdks drive progression through the eukaryotic cell cycle by forming complexes with cyclins ([@B31]; [@B25]; [@B16]; [@B6]; [@B41]). In most natural systems studied so far, levels of Cdks remain relatively constant during the cell cycle whereas levels of the cyclins oscillate, causing Cdk activity to oscillate. In experiments using engineered fission yeast, oscillations in Cdk activity alone, without the numerous additional regulatory mechanisms that normally affect the cell cycle, can be sufficient to drive orderly progression through major cell cycle events ([@B6]). Cdk6 specifically partners a particular type of cyclin (the D-type cyclins) and primarily regulates the G1 to S phase transition ([@B16]). In cerebral cortical progenitors, Pax6 negatively regulates the expression of Cdk6 ([@B30]).

Here we addressed several questions. Are the effects of Pax6 on the cell cycle likely to be mediated primarily through actions on Cdk6, or does Pax6 control multiple cell cycle regulators in parallel? Do the effects of Pax6 vary between cell cycle phases? Are levels of Cdk6 normally constant throughout the cell cycle of cortical progenitors? Does Pax6 modulate Cdk6 levels equally or differentially across the phases?

To address the first of these questions, we used quantitative real time polymerase chain reaction (qRT-PCR) to test for changes in the expression of a set of cell cycle regulators following acute cortical deletion of Pax6. The set we tested contained all cell cycle regulators that were shown in previous work to have altered cortical expression levels in constitutive *Pax6*^-/-^ mutants ([@B30]). Here we studied embryos with tamoxifen-induced cortex-specific deletion of Pax6. This allowed us to focus on the effects of Pax6 loss that are more likely to be direct by minimizing the possibility of secondary changes arising as a long-term consequence of cortical deletion or Pax6 removal from non-cortical tissues. We then used flow cytometry to discover how Pax6 affects the phases of the cell cycle and the levels of Cdk6 in each. We found that Pax6 loss increases Cdk6 levels similarly in all cell cycle phases and, particularly interestingly, that Cdk6 levels oscillate with cell cycle phase. This prompted us to extend our analysis to examine the relationship between Pax6 levels and Cdk6 levels across cell cycle phases. Our results indicated that Pax6 sets the level of expression around which Cdk6 oscillates but is unlikely to be responsible for controlling the oscillation itself.

Materials and Methods {#s1}
=====================

Mice and Tissue Preparation
---------------------------

All mice were bred in-house. The University of Edinburgh Animal Welfare and Ethics Board and a license from the Home Office UK issued under the UK Animals (Scientific Procedures) Act 1986 regulated all procedures. For constitutive inactivation of Pax6, we used the *Pax6*^Sey^ allele (designated as *Pax6^-^* here; ([@B15]). For conditional inactivation of Pax6, we used the *Pax6*^loxP^ allele ([@B39]) and a green fluorescent protein (GFP) reporter allele ([@B40]) with BAC transgenic strain *Emx1*^CreERT2^ ([@B18]). Dams were killed by cervical dislocation, fetuses were removed and cortices were dissected and used for RNA extraction (RNeasy Plus micro kit; Qiagen, Hilden, Germany) or dissociated with papain (20 U ml^-1^; Dissociation kit; Worthington Biochemical Corporation, Lakewood, NJ, United States). Dissociated cell suspensions diluted to 1.8 × 10^6^ ml^-1^ were fixed and permeabilised in 100% ethanol and stored at -20°C.

qRT-PCR
-------

cDNA was synthesized from RNA with a Superscript reverse transcriptase reaction (Thermo Fisher Scientific, Perth, United Kingdom) and qRT-PCR was done with a Quantitect SYBR Green PCR kit (Qiagen, Hilden, Germany) and a DNA Engine Opticon Continuous Fluorescence Detector (MJ Research, QC, Canada). Primer pairs are listed in Table [1](#T1){ref-type="table"}. For each sample, we normalized the abundance of each transcript to the GAPDH expression level and calculated the ratios of normalized expression levels in conditional knock outs (cKOs) to littermate controls. We used three biological replicates from three different litters. For each biological replicate we ran three technical replicates.

###### 

qRT-PCR primers.

  Gene                  Forward primer         Reverse primer
  --------------------- ---------------------- ----------------------
  *Pax6* (exons 6--7)   TATTACGAGACTGGCTCCAT   TTGATGACACACTGGGTATG
  *GFP*                 CAGCCACAACGTCTATATCA   GTGTTCTGCTGGTAGTGGTC
  *Cdk6*                GAGTGTCGGTTGCATCTTT    GAGTCCAATGATGTCCAAGA
  *Cdca7*               GGAACGTCCATGCTTACTTG   CACAACGTCGAGAACAAGAG
  *Smad2*               GCAGGAATTGAGCCACAGAG   CGGAGAGCCTGTGTCCATAC
  *Smad3*               GATGACTACAGCCATTCCAT   TCACTGGTTTCTCCATCTTC
  *Smad4*               TCCTGTGGCTTCCACAAGTC   ATGGTAAGTAGCTGGCTGAG
  *Smad7*               GTGTTGCTGTGAATCTTACG   CCATTGGGTATCTGGAGTAA
  *Cdk2*                GTGTACCCAGTACTGCCATC   TCCATGAATTTCTTGAGGTC
  *Cdk4*                GAGGACATACCTGGACAAAG   AGAATGTTCTCTGGCTTCAG
  *Ccnd1*               TTCATCGAACACTTCCTCTC   GAGGGTGGGTTGGAAAT
  *Ccnd2*               AGTGTGCATGTTCCTAGCTT   CAGGTTCCACTTCAGCTTAC
  *Sesn1*               TTGGCTGATTACCAAAGAAC   GAGGCAAGAGAGTGGTAGTG
  *Mcm3*                GGACGATATAGCCAAGATCA   GAGGATTGCCTTCTTGACAT
  *Mcm6*                GATTGTTGTGCCTGATGTCT   GACCAGCCTGTATGACAGAT
  *Smc2*                GACCAGAACTGTAACCCTTG   AGTTCATTCTCCTTGGTCCT
  *Ccdc80*              ATCTTTGGTCCTGTCAACAA   CATTCCATACTCCTTCCTCA
  *Ccdc90A*             GCACAGAAAAGAGAACTTGC   CAGTGCAGACACAATGATTT
                                               

Flow Cytometry
--------------

Aliquots of permeabilised and fixed cells suspended in fluorescence activated cell sorting (FACS) buffer were reacted with Hoechst 33342 (Thermo Fisher Scientific, Perth, United Kingdom; Cat\# 1391095). Primary antibodies used were: anti-Pax6 (1:200, rabbit, Millipore, Livingston, United Kingdom; Cat\# AB2237); anti-Tuj1 (1:800, mouse, Cambridge Bioscience, Cambridge, United Kingdom; Cat\# MMS 435P); anti-PH3 (1:200, mouse, Cell Signaling Technology, Danvers, Massachusetts, United States; Cat\# 9706); anti-Ki67 (1:500, rat, eBioscience, San Diego, CA, United States; Cat\# 12-5698); anti-Cdk6 (1:500, rabbit, Santa Cruz Biotechnology, Dallas, TX, United States; Cat\# SC-177). We used secondary-only and fluorescence-minus-one controls to set thresholds for primary antibody-specific staining. Cells were analyzed using an LSRII flow cytometer and FlowJo V10 software (BD Biosciences, Franklin Lakes, NJ, United States). In all of our experiments, we used the same gate for forward scatter for both wild-type and mutant progenitor cells. Since forward scatter values in flow cytometry are directly linked to cell size, this indicates that the wild-type and mutant cells were in the same size range.

Immunohistochemistry for BrdU and IdU
-------------------------------------

Pregnant females were injected intra-peritoneally with 200 μl of 100 μg ml^-1^ IdU and then 1.5 h later with the same dose of BrdU. They were sacrificed after 30 min and histological sections were cut through the cortex. Primary antibodies used were anti-BrdU/IddU (which recognizes both BrdU and IddU) (1:100, mouse, Becton Dickinson, Swindon, United Kingdom; clone B44) and anti-BrdU (1:100, rat, Abcam, Cambridge, United Kingdom; clone BU1/75). Nuclei were counterstained with TO-PRO-3 iodide (Molecular Probes). Analysis was as described in ([@B29]).

Results
=======

Changes in the Expression of Cell Cycle Regulators Following Acute Cortical Deletion of Pax6
--------------------------------------------------------------------------------------------

We gave tamoxifen to experimental *Pax6*^fl/fl^;*Emx1*^CreER^ (designated cKO) and littermate control *Pax6*^fl/+^;*Emx1*^CreER^ embryos at E9.5. All embryos contained a floxed-stop *GFP* reporter allele ([@B40]). We used qRT-PCR to measure levels of mRNA in cortical samples relative to levels of *GAPDH*. For all genes except *GFP* we then calculated ratios between the relative mRNA levels in cKO and control littermates at E11.5, 12.5, and 13.5 (Figure [1](#F1){ref-type="fig"}).

![Quantitative RT-PCR analysis of the effects of tamoxifen-induced cortex-specific Pax6 deletion on the expression of cell cycle genes. **(A)** Tamoxifen given at E9.5 resulted in *Pax6* mRNA loss, with a ∼60% reduction by E11.5 and a ∼100% reduction by E13.5. **(B)** This loss coincided with the production of increasing levels of *GFP* reporter gene mRNA. **(C--R)** Changes in the expression of 16 cell cycle genes. In all cases, the levels of cortical expression of each gene were measured relative to levels of cortical expression of *GAPDH* in the same embryo. In panels **(A)** and **(C--R)**, ratios of expression in conditional knock-outs (cKO) over littermate controls were combined to give mean ± SEM at each age. All data are from three biological replicates at each age; ^∗^*p* \< 0.05; ^∗∗^*p* \< 0.01; Student's *t*-test comparison of cKOs with paired controls at each age.](fncel-12-00419-g001){#F1}

*Pax6* levels decayed exponentially and *GFP* levels rose steadily over the 4 days following tamoxifen administration (Figures [1A,B](#F1){ref-type="fig"}). *Pax6* levels had declined to ∼40% of normal by E11.5, the earliest post-tamoxifen time-point examined. *Cdk6* was the only cell cycle gene studied that showed a significant change (upregulation) in gene expression at E12.5 and this was sustained at E13.5 (Figure [1C](#F1){ref-type="fig"}). *Cdca7* showed a significant upregulation but only later, at E13.5 (Figure [1D](#F1){ref-type="fig"}). *Smad3*, *Smad7*, and *Sesn1* showed significant downregulation but only at E13.5 (Figures [1F,H,M](#F1){ref-type="fig"}). These results suggest that no other Pax6-regulated cell cycle gene rivals *Cdk6* as the top candidate among possible mediators of Pax6's actions on cortical progenitor cell cycle lengths. Whereas genes such as *Cdca7*, *Smad3*, *Smad7*, and *Sesn1* are almost certainly involved, it is possible that they alter their expression as a secondary consequence of changes in *Cdk6* expression.

G1 Is Abnormally Short in *Pax6*^-/-^ Mutants
---------------------------------------------

Given that Cdk6's main action during the eukaryotic cell cycle is to promote the G1 to S phase transition ([@B16]), we hypothesized that elevation of Cdk6 in *Pax6*^-/-^ mutants might shorten the cell cycle of cortical progenitors by shortening primarily G1 phase. We first estimated the overall lengths of the cell cycles (Tc) of progenitors in *Pax6*^+/+^ and *Pax6*^-/-^ E12.5 and E14.5 cortex using double labeling with iododeoxyuridine (IdU) and bromodeoxyuridine (BrdU) ([@B29]). At E12.5, Tc was ∼10% shorter in *Pax6*^-/-^ cortex than in *Pax6*^+/+^ cortex (*n* = 3 embryos of each genotype from three different litters; mean Tc ± SEM = 12.1 ± 0.15 h in *Pax6*^+/+^ and 10.75 ± 0.06 h in *Pax6*^-/-^; *p* = 0.0099, Student's *t*-test). At E14.5, Tc was ∼15% shorter in *Pax6*^-/-^ cortex than in *Pax6*^+/+^ cortex (*n* = 3 embryos of each genotype from three different litters; mean Tc ± SEM = 18.0 ± 0.41 h in *Pax6*^+/+^ and 15.5 ± 0.42 h in *Pax6*^-/-^; *p* = 0.0004, Student's *t*-test) (Figure [2](#F2){ref-type="fig"}).

![Cell cycle lengths are shortened in *Pax6*^-/-^ progenitors. Lengths of the cell cycles of progenitors in *Pax6*^+/+^ and *Pax6*^-/-^ E12.5 and E14.5 cortex measured using double labeling with IdU and BrdU \[*n* = 3 embryos of each genotype from three different litters for each age; mean ± SEMs are shown; in panel **(A)**, *p* = 0.0099, Student's *t*-test; in panel **(B)**, *p* = 0.0004, Student's *t*-test\].](fncel-12-00419-g002){#F2}

We then used flow cytometry to quantify the relative lengths of G1, S, G2, and M phases in cortical cells from E12.5 and E14.5 *Pax6*^+/+^ and *Pax6*^-/-^ embryos (Figure [3](#F3){ref-type="fig"}). A combination of Hoechst and antibody staining identified cells in each of the phases (Figures [3A](#F3){ref-type="fig"}--[F](#F3){ref-type="fig"}). Cells were labeled with Hoechst 33342 to measure DNA content and antibodies for Ki67 (a marker of proliferating cells), class III beta-tubulin (TuJ1; a marker of postmitotic neurons), phospho-Histone H3 (PH3; a marker of M phase), and Pax6. Cells were classified as G1 if they had 2n DNA content and were positive for Ki67 (Figure [3A](#F3){ref-type="fig"}). As expected, almost all of these cells (∼98%) were negative for TuJ1 (Figure [3C](#F3){ref-type="fig"}). Combining data from multiple embryos (four per genotype per age) showed significant reductions by ∼8--10% in the proportions of cells in G1 at both ages in *Pax6*^-/-^ embryos (Figures [3G,H](#F3){ref-type="fig"}). For phases other than G1, the only significant differences were in S and G2 at E14.5 (Figures [3G,H](#F3){ref-type="fig"}), where mean values were higher in mutants in both cases.

![Flow cytometric analysis of cell cycle phases of cortical progenitors in *Pax6*^+/+^ and *Pax6*^-/-^ embryos at E12.5 and E14.5. **(A--F)** Representative examples of flow cytometry showing how cells were assigned to specific stages of the cell cycle. Cells were labeled with Hoechst 33342 and antibodies for Ki67, class III beta-tubulin (TuJ1), phospho-Histone H3 (PH3) and Pax6. **(A)** Fluorescence intensity of Ki67 against Hoechst, shown as a heat-map with red areas containing most cells and blue areas fewest: Cells were classified as G1 if they had 2n DNA content and were positive for Ki67 (intensity values above the red line), which is a marker of proliferating cells. **(B)** Fluorescence intensity of TuJ1 against Hoechst: TuJ1 was used as a marker of differentiating neurons. **(C)** Fluorescence intensity of Ki67 against TuJ1, with different colors indicating cell cycle phase of each cell: In this sample, 98.0% (50.7/51.74) of Ki67+ cells were TuJ1-- whereas 69.3% (33.5/48.3) of Ki67-- cells were Tuj1+. **(D)** Fluorescence intensity of PH3 against Hoechst, plotted using the same method as in panel **(A)**: Cells in M phase were identified by their expression of PH3 (0.858%, above black line). **(E)** Fluorescence intensity of Ki67 against Hoechst: M phase cells expressed PH3 and contained the highest levels of Ki67. **(F)** Fluorescence intensity of Pax6 against Ki67, plotted using the same method as in panel **(C)**: Very few Ki67-- cells expressed Pax6 (11.5% \[6.72/58.52\] in this sample) whereas most Ki67+ cells co-expressed Pax6 (74.7% \[31/40.5\] in this sample). **(G,H)** Proportions of proliferating cells (i.e., G0 cells excluded) in each phase of the cell cycle in *Pax6*^+/+^ and *Pax6*^-/-^ embryos at E12.5 and E14.5. Values are mean ± SEM (*n* = 4 embryos in all cases). ANOVA showed a significant effect of genotype at both ages (α = 0.05). Significant effects of genotype on each phase at each age are marked (Sidak's multiple comparisons tests: ^∗∗^*p* = 0.0029; ^∗∗∗^*p* = 0.0001; ^∗∗∗∗^*p* \< 0.0001). **(I--L)** Charts, drawn to scale, summarizing the relative lengths of the cell cycle phases across ages and genotypes.](fncel-12-00419-g003){#F3}

We estimated the lengths of each phase in hours under different conditions by multiplying the proportion of cells in that phase by the corresponding Tc derived from calculations above. These estimations gave values for G1 of 9.3 h in *Pax6*^+/+^ cortex and 7.7 h in *Pax6*^-/-^ cortex at E12.5. At E14.5, values for G1 were 14.8 h in *Pax6*^+/+^ cortex and 11.5 h in *Pax6*^-/-^ cortex. At E12.5, S phase was 1.7 h in *Pax6*^+/+^ cortex versus 1.8 h in *Pax6*^-/-^ cortex, G2 phase was 0.9 h in *Pax6*^+/+^ cortex versus 1.0 h in *Pax6*^-/-^ cortex and M phase was 0.2 h in *Pax6*^+/+^ cortex versus 0.25 h in *Pax6*^-/-^ cortex. At E14.5, S phase was 1.9 h in *Pax6*^+/+^ cortex versus 2.2 h in *Pax6*^-/-^ cortex, G2 phase was 1.3 h in *Pax6*^+/+^ cortex versus 1.6 h in *Pax6*^-/-^ cortex, and M phase was 0.1 h in *Pax6*^+/+^ cortex versus 0.2 h in *Pax6*^-/-^ cortex. These estimations are summarized graphically in Figures [3I](#F3){ref-type="fig"}--[L](#F3){ref-type="fig"}. These data suggest that in the absence of Pax6 G1 phase is shortened by ∼2--3 h while other phases are similar to or ∼15--20 min longer than normal.

Cdk6 Levels Are Elevated During All Phases of the Cell Cycle in *Pax6*^-/-^ Cortical Progenitors
------------------------------------------------------------------------------------------------

In most systems studied to date, levels of Cdks remain relatively constant during the cell cycle ([@B16]). It was not known whether this is also the case for cortical progenitors and whether the absence of Pax6 affects Cdk6 levels in all phases of the cortical progenitor cell cycle. We used flow cytometry to identify cells in each cell cycle phase (Figures [3A](#F3){ref-type="fig"}--[F](#F3){ref-type="fig"}) and measure their Cdk6 levels. We found significantly elevated levels of Cdk6 in all cell cycle phases of *Pax6*^-/-^ progenitors (Figure [4C](#F4){ref-type="fig"}). In addition, Cdk6 levels varied across the phases, rising by ∼1.5--2-fold from G1 to M both in *Pax6*^+/+^ and *Pax6*^-/-^ progenitors (Figure [4C](#F4){ref-type="fig"}).

![Flow cytometric analysis of Cdk6 levels at different phases of the cell cycle in *Pax6*^+/+^ and *Pax6*^-/-^ cortex at E12.5. **(A,B)** Fluorescence intensity of Cdk6 against Ki67: Samples from a *Pax6*^+/+^ and a *Pax6*^-/-^ embryo with cells classified according to their cell cycle phase by methods illustrated in Figure [3](#F3){ref-type="fig"}. G1 cells were distinguished from G0 cells by positivity for Ki67 in quadrants Q2-1 and Q4-1 (cells in quadrants 1-1 and 3-1 were negative for Ki67). **(C)** Relative levels of Cdk6 in the cortex of four *Pax6*^+/+^ and four *Pax6*^-/-^ embryos at each phase of the cell cycle. Each data point is the average level in the cortex of one embryo. Regression analysis of levels of Cdk6 against cells cycle phase gave *r*^2^ values of 0.78 for *Pax6*^+/+^ data and 0.81 for *Pax6*^-/-^ data. ANOVA showed a significant effect of genotype (α = 0.05) and Sidak's multiple comparisons tests showed significantly higher levels of Cdk6 in *Pax6*^-/-^ cortex in all phases (G1, *p* = 0.0075; S, *p* \< 0.0001; G2, *p* = 0.0167; M, *p* = 0.0019).](fncel-12-00419-g004){#F4}

Pax6 Levels Oscillate During the Cell Cycle in Cortical Progenitors
-------------------------------------------------------------------

A parsimonious explanation for the fact that Cdk6 levels oscillate not only in *Pax6*^+/+^ cortex but also in *Pax6*^-/-^ cortex is that Pax6 influences the average level of Cdk6 expression rather than being directly responsible for the oscillations themselves, which would be caused by a different mechanism. This would explain why Cdk6 levels still oscillate in the absence of Pax6. Nonetheless, a more complex scenario was conceivable. In normal cortex, Pax6 levels might oscillate during the cell cycle in such a way as to drive changes in Cdk6 levels; in *Pax6*^-/-^ cortex, some other unknown mechanism might take over Pax6's role. We addressed whether this second possibility might be feasible by measuring Pax6 levels in each phase of the cell cycle in normal embryos using flow cytometry (Figure [5](#F5){ref-type="fig"}).

![Flow cytometric analysis of Pax6 levels at different phases of the cell cycle in *Pax6*^+/+^ cortex at E12.5, E13.5, and E14.5. Cells classified according to their cell cycle phase by methods illustrated in Figure [1](#F1){ref-type="fig"}. **(A)** Example showing how M phase cells were identified by their expression of PH3. **(B)** Example showing how G1 cells were distinguished from G0 cells by positivity for Ki67. **(C--E)** Average relative levels (± SEM) of Pax6 in proliferating cortical cells (G0 cells excluded) in each cell cycle phase in rostral and caudal cortex (*n* = 4 embryos at each age). ANOVAs at each age showed significant effects of cell cycle phase (α = 0.05). Sidak's multiple comparisons tests showed significant differences between phases, as marked (^∗^*p* \< 0.05; ^∗∗^*p* \< 0.001; ^∗∗∗^*p* \< 0.0001).](fncel-12-00419-g005){#F5}

We identified cells in each phase using methods illustrated in Figures [3](#F3){ref-type="fig"}, [5A,B](#F5){ref-type="fig"}. We found that Pax6 levels varied significantly with cell cycle phase at all ages studied (Figures [5C](#F5){ref-type="fig"}--[E](#F5){ref-type="fig"}). In most phases at E12.5 and E13.5 (the one exception being M phase at E13.5), Pax6 levels were significantly higher in rostral than in caudal cortex (*p* \< 0.01 in all phases at both ages, Sidak's multiple comparisons tests following ANOVA, α = 0.05). This was only the case in G1 at E14.5 (*p* \< 0.01). These findings on rostral versus caudal differences are in excellent agreement with previous work showing a rostral \[high\] to caudal \[low\] gradient of Pax6 expression at E12.5 and E13.5 that flattens by E14.5 ([@B30]).

Pax6 levels changed by ∼1.5--2-fold from trough to peak during the cell cycle (Figures [5C](#F5){ref-type="fig"}--[E](#F5){ref-type="fig"}). The oscillations in Pax6 levels were out of phase with the oscillations in Cdk6 levels shown in Figure [4](#F4){ref-type="fig"}. Levels rose to a peak in G2 and dropped in M, before Cdk6 levels fell. The rise of Pax6 from G1 to G2 paralleled that of Cdk6 through these three phases.

Discussion
==========

Our new results support a central role for Cdk6 in Pax6's regulation of cortical progenitor cell cycles. Figure [6](#F6){ref-type="fig"} shows a model illustrating how elevated Cdk6 levels across the cell cycle could shorten G1 phase. We propose that the time of G1 and the G1 to S phase transition is determined by the time it takes Cdk6 activity to rise above a threshold; our model proposes that the threshold is similar in both *Pax6*^+/+^ and *Pax6*^-/-^ progenitors (Figures [6B,C](#F6){ref-type="fig"}). Oscillation of Cdk6 activity at abnormally high levels would shorten the length of G1 since it would take less time to achieve the threshold required to exit G1. We also found evidence that other cell cycle phases were slightly longer than normal in *Pax6*^-/-^ progenitors, particularly at the later age studied, E14.5. This is reflected in the way Figure [6](#F6){ref-type="fig"} is drawn. These changes were not enough to compensate for the shortening of G1 and, overall, cell cycle lengths were reduced. We do not know how these other phases might be affected. At least one possibility is that they are lengthened as a consequence of accelerated progression through G1 phase rather than a direct action of Pax6 on regulators of these phases. Another possibility is that delayed changes in the expression of cell cycle genes other than *Cdk6*, such as those observed here (Figure [1](#F1){ref-type="fig"}: *Cdca7*, *Smad3*, *Smad7*, or *Sesn1*) directly affect the lengths of these phases.

![A model. **(A,B)** Pax6 and Cdk6 oscillations are slightly out of phase. **(C)** A general elevation of Cdk6 activity throughout the cell cycle might allow levels critical for switching from G1 to S (horizontal line in **B,C**) to be achieved more rapidly than normal.](fncel-12-00419-g006){#F6}

This proposal has similarity to the mechanism proposed to regulate an engineered minimal control network in fission yeast ([@B6]). This control network is based on oscillating levels of CDK activity, which drive cell cycle progression as they cross thresholds triggering transition between cell cycle phases including G1 to S. As in the fission yeast model, it is possible that the oscillations in Cdk6 in cortical progenitors result from phase-dependent changes in Cdk6 synthesis and degradation.

An alternative possibility is that cyclical changes in Pax6 levels might cause the oscillations in Cdk6 levels, given that Pax6 can directly repress Cdk6 expression ([@B30]). The oscillations in Pax6 were slightly out of phase with those in Cdk6 (Figures [6A,B](#F6){ref-type="fig"}) but it is very unlikely that fluctuations in Pax6 protein levels alone cause the oscillations in Cdk6 protein levels. Additional factors would be required to explain the very different rates of change of Pax6 during its rising phase and Cdk6 during its falling phase and *vice versa*. An additional complexity would be explaining the dynamics of this scenario. Changes in Pax6 protein levels would need a certain time to influence transcription of the *Cdk6* gene and the mRNA would then need to be translated to alter Cdk6 protein levels. Although we do not exclude the possibility that fluctuations in Pax6 levels might contribute to the temporal pattern of change of Cdk6 levels, the simplest suggestion is that Pax6 reduces Cdk6 levels overall and that the oscillations in Cdk6 levels during the cell cycle are driven by other mechanisms. Our previous work showed that Pax6 overexpression significantly reduced Cdk6 levels ([@B30]), and in the future it would be interesting to test how Cdk6 levels oscillate during the cell cycle in these mutants and how cell cycle phases change.

It is likely that post-translational processes are involved in the relatively rapid cyclical changes in Cdk6 and Pax6 levels identified here. Cortical progenitor cells might generate excess amounts of their mRNAs, which might be translated at levels that vary as the cell progresses through the cell cycle. A similar mechanism, termed "translation on demand," was suggested in a recently published review paper ([@B24]). It suggests that quick generation of proteins in response to signals could be achieved purely by regulating the translation rate of pre-existing mRNA ([@B21]; [@B23]; [@B19]; [@B8]; [@B17]). Some studies suggested that transcription factors are more likely to be subject to translation on demand regulation, as some rapid cell state transitions require fast synthesis and reactions of transcription factors to modulate their downstream gene networks ([@B22]; [@B17]; [@B24]). Rapid degradation via ubiquitination might also contribute to rapid adjustments of Pax6 and Cdk6 protein levels during the cell cycle. In eye development, for example, a post-translational ubiquitin-mediated proteasomal mechanism degrades Pax6 protein ([@B34]). It is possible that Pax6 regulates the overall levels of Cdk6 not only by direct repression of the *Cdk6* gene itself ([@B30]) but also by affecting the post-translational mechanisms that determine Cdk6 protein production and stability.

A Pax6-loss-induced change in the length of G1 phase is likely to have consequences for the subsequent development of progenitors and the neurons that they generate. Previous studies have shown that cell cycle length has a direct impact on a cell's mode of division, i.e., whether it is neurogenic, producing neurons, or proliferative, producing new progenitor(s). G1 length is increased in neurogenic progenitors compared with proliferative progenitors ([@B5]; [@B26]; [@B7]; [@B37]). This is in line with the finding that basal progenitors, which mostly generate neurons through neurogenic division, have a longer G1 phase than apical progenitors ([@B4]; [@B37]; [@B1]). The functional importance of G1 length was demonstrated by manipulating it. An increase in G1 length leads to neurogenic division and premature neurogenesis ([@B3]; [@B4]). Shortening G1 increases proliferative divisions, leading to an expansion of the progenitor pool, and affects laminar phenotypes later in development ([@B20]; [@B35]). This might be one mechanism by which Pax6 affects the later stages of cortical formation despite being downregulated in postmitotic neurons.

Author Contributions
====================

DM, MM, and Y-TH performed the experiments. DP and JM helped to design the experiments, obtained the funding, and supervised the work. DP wrote the manuscript.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This research was funded by MRC grant N012291 and BBSRC grant N006542.

We thank Dr. Martin Waterfall at the Flow Cytometry Core Facility for his generous support, Dr. Thomas Tan at the School of Biological Sciences for technical assistance and Mr. Chenyi Wang at the Department of Clinical Neurosciences, University of Cambridge for the precious help of flow cytometry analysis.

[^1]: Edited by: Tommaso Pizzorusso, Consiglio Nazionale delle Ricerche (CNR), Italy

[^2]: Reviewed by: Michele Studer, Institut National de la Santé et de la Recherche Médicale (INSERM), France; Federico Cremisi, Scuola Normale Superiore di Pisa, Italy

[^3]: ^†^Present address: *Da Mi, Centre for Developmental Neurobiology, Institute of Psychiatry, Psychology and Neuroscience and MRC Centre for Neurodevelopmental Disorders, King's College London, London, United Kingdom*
